Trimethoprim (UTI)
Brand names: Monotrim
Trimethoprim is an oral antibacterial widely used as first-line short-course treatment for uncomplicated lower urinary tract infection, where local resistance allows.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits bacterial dihydrofolate reductase, blocking folate synthesis and thereby bacterial DNA and protein production.
Prescribing in practice
- Avoid in the first trimester of pregnancy because its folate-antagonist action carries a risk of neural tube defects; choose an alternative and give folate where exposure occurs.
- It can cause hyperkalaemia and raise serum creatinine, with particular caution alongside ACE inhibitors, angiotensin receptor blockers, potassium-sparing agents and in renal impairment.
- Concurrent use with methotrexate increases the risk of folate-related bone marrow toxicity.
Monitoring
For short courses little monitoring is needed, but check renal function and potassium with prolonged use, in the elderly or with interacting drugs.
Counselling the patient
- Complete the prescribed course and seek review if symptoms persist or worsen.
- Tell your prescriber if you are or might be pregnant.
Evidence & guidelines
NICE urinary tract infection guidance lists trimethoprim as an empirical option for lower UTI, with choice guided by local resistance patterns.
Reference: NICE NG112; PHE antimicrobial guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis